Cargando…
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus (KSHV). PEL prognosis is poor and patients barely survive more than 6 months even following active chemotherapy in...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578886/ https://www.ncbi.nlm.nih.gov/pubmed/28459467 http://dx.doi.org/10.1038/onc.2017.122 |